Johannes Wohlrab, MD; Alexandra Goebel, PhD; Dieter Scherer, PhD; Debra Bingham, and Reinhard H.H. Neubert, PhD, develop a colloidal preparation, a microemulsion, that meets the specific conditions for penetration of the psoriatic skin and achieves the required bioavailability of the drug in the underlying tissue, which cannot be achieved by conventional formulations.
THERAPEUTIC FOCUS – Drug Development for the Management of Type 2 Diabetes – Glucose Control Is No Longer Enough
Senior Industry Analyst Debbie Toscano reports the trend in diabetes drug development is moving away from simply controlling blood glucose toward addressing the other important risk factors and comorbidities, primarily obesity and cardiovascular disease.
Srikanth Kakumanu, PhD, and Avi Schroeder, PhD, describe a novel technology capable of efficiently producing nanoliposome formulations at the bench or in a pilot plant, eliminating the need to heat the lipids or dissolve them in a co-solvent during the formulation process.
DRUG DELIVERY – Tunable Half-Life Extension Based on Recombinant Albumin – Tailoring Pharmaceuticals to Specific Medical Needs
Mark Perkins, PhD, reviews the development of a tunable half-life technology to serve as a flexible drug delivery platform designed to enable manufacturers to tailor protein or peptide half-lives to specific medical needs.
FORMULATION DEVELOPMENT – Next-Generation PEGylation Enables Reduced Immunoreactivity of PEG-Protein Conjugates
Merry R. Sherman, PhD; Mark G.P. Saifer, PhD; L. David Williams, PhD; Shawnya J. Michaels, MS; and Monika A. Sobczyk, MS; illustrate the close parallels between the results of Armstrong et al with respect to anti-PEG antibodies detected in sera of ALL patients treated with mPEG-asparaginase and the results reported by Sundy et al based on the Phase III clinical trials of mPEG-uricase in patients with RCG
Dr. Rod Ray, CEO and Chairman at Bend Research, discusses his company’s approach to difficult drug delivery challenges and the core technologies offered by his company.
Dr. Jean-Luc Herbeaux, the Head of the Health Care Business Line of Evonik, discusses the rationale and success of his company’s latest acquisition.
EXECUTIVE INTERVIEW – Ezose Sciences: High-Throughput Glycomics for Biomarker Discovery – Bringing Glycan Analysis Into Everyday Research
Scott Siegel, PhD, VP of Business Development at Ezose, discusses how his unique company is catalyzing progress across an emerging research front.
Jos Raats, PhD, says ModiQuest has undertaken a number of studies into specific anti-Citrulline antibodies and has discovered a subset (family) of rCit-hMabs, which could provide a valuable therapeutic in the treatment of early onset RA.
Carl Levoguer, PhD, examines how laser diffraction technology has been fashioned to powerfully support every stage of the drug development cycle.
EXCLUSIVE ONLINE CONTENT
Soligenix, Inc. recently announced today it has reached a significant milestone in the Phase 3 clinical study (the “DOM-INNATE” study) for SGX942 (dusquetide) in the treatment of oral mucositis in patients with head and neck cancer (HNC).
Catalent, Inc. and Paragon Bioservices, Inc. and Catalent Inc. recently announced they have entered into a definitive agreement under which Catalent will acquire Paragon for $1.2 billion.
BioAtla , LLC and BeiGene, Ltd. recently announced the two companies have entered into a global co-development and collaboration agreement for the development, manufacturing, and commercialization of BioAtla’s investigational CAB CTLA-4 antibody (BA3071).
Ajinomoto Bio-Pharma Services, a leading provider of biopharmaceutical contract development and manufacturing services, recently announced that GeneDesign, Inc. has joined the global organization.
CURE Pharmaceutical, an innovative drug delivery and development company, recently announced that it has agreed to acquire Chemistry Holdings Inc., a formulation technology company that is developing innovative delivery systems for a variety of industries, in an all-stock transaction.